BioEscalator · Aug 2024
Confirms YC acceptance and says the company would receive funding plus advice/support to continue R&D.
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Oxford-based biotech startup founded in 2021 that is building AI- and evolution-informed precision antibiotics to outpace bacterial resistance; it is small, founder-led, and YC S24-associated. Public funding sources are a little inconsistent, but the company profile most directly indicates $625K total raised across a $125K Seed and a $500K Pre-Seed.
Primary product
AI-powered precision-antibiotics discovery platform
Founded
2021
Headquarters
Oxford, Oxfordshire, United Kingdom
Team size
1-10
Industry
Biotechnology
Sub-industry
Antibiotic discovery
Offices
Oxford, United Kingdom (BioEscalator / Old Road Campus)
167-169 Great Portland Street, London W1W 5PF, United Kingdom (registered office)
Business model
drug discovery platform
therapeutics development
AI model licensing
Funding
People & investors
Leadership
CEO & Co-Founder
CTO & Co-Founder
CSO & Co-Founder
Work & culture
Mission-driven and research-heavy, with public materials emphasizing diversity, inclusion, mentoring, and close ties to the Oxford/BioEscalator ecosystem.
Product & market
Pricing
B2B licensing and partnership-based; no public list pricing found.
Differentiators
- —Uses co-evolutionary datasets plus AI to forecast bacterial mutations
- —Targets pathogenic bacteria while aiming to preserve beneficial microbes and human cells
- —Positions antibiotics as 'future-proof' against resistance
- —Combines synthetic biology, bioinformatics, and computational modeling
- —Also explores licenseable AI models for other companies
Technology
AI
computational models
co-evolutionary protein-protein interaction datasets
synthetic biology
bioinformatics
protein engineering
automation
Customers
pharmaceutical companies
biotech partners
research institutions
drug-development partners
Competitors
Spero Therapeutics
Nimbus Therapeutics
Generate Biomedicines
Vedanta Biosciences
Locus Biosciences
Cradle
Profluent Bio
Frontier Medicines
Scale & contact
Latest news
LinkedIn · Aug 2024
Adam Winnifrith’s launch post describes the company’s foundation-model approach to evolution-aware antibiotic design and credits the Oxford/BioEscalator network.
BioEscalator · May 2024
Explains the company’s AMR mission, its AI/synthetic-biology platform, its Innovate UK grant support, and its plan to prepare for venture funding.
AMR Insights · Dec 2022
Lists Evolvere Biosciences with Adam Winnifrith as CEO & Co-Founder and publishes a public contact phone/email for the company contact.
BioEscalator · Jun 2022
Earlier profile of the company’s formation, Oxford student founders, and its platform idea for outsmarting antibiotic resistance.
Jobs and careers at Evolvere BioSciences
0 jobs at Evolvere BioSciences
No open positions
Check back later for new openings